1. Medtech Insight
  2. >>Device Area
  3. >>Ophthalmology

How Open Science Is Keeping Allergan's R&D Pipeline Strong

 
• By Tina Tan

Allergan's chief R&D officer David Nicholson discusses the company's "open science model" to innovation and innovating, and highlights some of the promising device-based technologies it recently acquired and is developing.

Innovation is a key pillar in the growth strategy of any life-sciences company, but according to David Nicholson, chief research and development officer of specialty pharmaceutical firm Allergan PLC, it is also the biggest challenge.

"You need to focus, you need to interact with the external world and make sure the pipeline is full of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ophthalmology

A Clearer Future For Nearsighted Children? FDA Authorizes Novel Eyeglass Lens To Correct Myopia

 
• By Brian Bossetta

The US FDA authorization of the Stellest eyeglass lens from French firm EssilorLuxottica could be game-changing for children with myopia, or nearsightedness. The lenses are designed to slow myopia’s progression in children aged 6 to 12.

Alcon Drops Revenue Projections After Soft Q2 Sales

 
• By Elizabeth Orr

The vision company expects total annual revenues of $10.3bn-$10.4bn, marking a slower growth rate than earlier forecasts. However, management remains optimistic that overall trends, as well as recent purchases like STAAR and LumiThera, represent a significant market opportunity.

ForSight Sets Its Sights On Automating Delicate Eye Procedures

 
• By Marion Webb

ForSight Robotics is developing a robotic platform to automate cataract and other eye surgeries, aiming to ease surgeon strain and expand access. Backed by $200m in total funding, it's targeting a first human surgery using Oryom by year-end and is in discussions with US FDA.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 
• By Natasha Barrow

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.

More from Device Area

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.